Advances in cancer biology - metastasis最新文献

{"title":"Decoding EMT through liquid biopsy: A path to early detection and targeted therapy","authors":"Revathi Boyina ,&nbsp;Prasanna Kumar Desu ,&nbsp;Sreya Kosanam ,&nbsp;Anusha Rapuri ,&nbsp;Ramesh Alluri ,&nbsp;Jadala Shankaraswamy ,&nbsp;Sri Chandana Mavulati ,&nbsp;Vanitha Kondi","doi":"10.1016/j.adcanc.2025.100141","DOIUrl":"10.1016/j.adcanc.2025.100141","url":null,"abstract":"<div><div>Epithelial-mesenchymal transition (EMT) is a key biological process that enables cancer cells to acquire invasive, migratory, and therapy-resistant properties, driving metastasis and poor clinical outcomes. Traditional tissue biopsies, while informative, provide only static and localized snapshots of tumors, limiting their ability to capture dynamic changes like EMT. Liquid biopsy has emerged as a powerful, minimally invasive tool to monitor tumor evolution in real time by analyzing circulating tumor cells (CTCs), cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs) from body fluids. This review highlights the molecular mechanisms that govern EMT, including transcriptional, signaling, and epigenetic regulation, and discusses how EMT-associated alterations can be detected through liquid biopsy. We explore the clinical applications of EMT monitoring via liquid biopsy for early detection of metastasis, prognostic assessment, therapy selection, and monitoring minimal residual disease (MRD). Despite current challenges such as the biological complexity of EMT, detection sensitivity, and the need for standardization, technological advances and emerging computational tools are paving the way for the integration of liquid biopsy into precision oncology. Understanding and decoding EMT through liquid biopsy represents a promising frontier for improving cancer diagnosis, prognosis, and therapeutic strategies, offering hope for more personalized and effective cancer management in the future.</div></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"15 ","pages":"Article 100141"},"PeriodicalIF":2.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144329774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The targeted delivery of anti-metastasis oligonucleotide in breast cancer cells by the nanoliposomes conjugated with RGD ligand","authors":"Farahanaz Kavian Manesh ,&nbsp;Ali Jebali ,&nbsp;Flora Forouzesh","doi":"10.1016/j.adcanc.2025.100140","DOIUrl":"10.1016/j.adcanc.2025.100140","url":null,"abstract":"<div><div>To decrease the <em>ETV4</em> gene, which is important in metastasis, the nanoliposome containing ETV4 antisense oligonucleotide conjugated with Arginylglycylaspartic acid (RGD) ligand was used in the study. The nanoliposome containing ETV4 antisense oligonucleotide conjugated with RGD ligand was synthesized and characterized by AFM, DLS, and FTIR. Then, MDA-MB-231, MCF-7, and MCF-10A cell lines were treated with different concentrations of nanoliposomes containing antisense ETV4 oligonucleotide conjugated with RGD, nanoliposomes without antisense ETV4 oligonucleotide, and antisense ETV4 oligonucleotide for 24 h. Finally, an MTT assay was used to evaluate cell viability, Real-time PCR was employed to assess the <em>ETV4</em> mRNA expression, and western blotting was applied to evaluate the expression of ETV4 protein. Here, the characterization data revealed that the nanoliposome containing antisense ETV4 oligonucleotide conjugated with RGD had a spherical shape with a size range of 50–120 nm and zeta potential of −18mV to +7 mV. This study showed that although nanoliposomes containing antisense ETV4 oligonucleotide conjugated with RGD could effectively decrease the cell viability of MDA-MB-231 and MCF-7 cells, they could not dcrease cell viability of MCF-10A, indicating the effect of RGD ligand. Also, this novel carrier could decrease both mRNA and protein of <em>the ETV4</em> gene in a dose dependent manner.</div></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"14 ","pages":"Article 100140"},"PeriodicalIF":2.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143895474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the apoptotic and antimetastatic effect of daphnetin-containing nano niosomes on MCF-7 cells","authors":"Saeed Homaeii,&nbsp;Mahsa Kavousi,&nbsp;Elahe Ali Asgari","doi":"10.1016/j.adcanc.2025.100139","DOIUrl":"10.1016/j.adcanc.2025.100139","url":null,"abstract":"<div><div>Breast cancer is the most common cancer in the world and the second leading cause of cancer-related deaths in women worldwide. Although great progress has been made in elucidating the molecular features and underlying pathogenesis of breast tumors and various therapeutic strategies have been applied for individualized treatment, some types of breast cancer patients with aggressive features have a poor prognosis in terms of treatment. Nanotechnology is increasingly used in biology and medicine, including as a tool for diagnosing, treating and targeting tumors. The aim of this study is therefore to develop a drug delivery system based on niosomes loaded with daphnetin, a phytochemical coumarin. To confirm the synthesis of the loaded nano niosome, their physical and chemical properties were examined using SEM, FTIR and DLS. In this study, the toxic effect of daphnetin-loaded nanoparticles on the MCF-7 cell line was measured using the MTT assay. The expression level of apoptotic genes <em>Bax</em> and <em>Caspase 3</em>; and metastatic genes <em>MMP2</em> and <em>ITGA5</em> were quantitatively evaluated using the Real-time PCR method, and the division and metastatic potential of cancer cells were qualitatively evaluated by performing the scratch (repair) method. Finally, the effect of the investigated compounds on the amount of apoptosis and necrosis and the induced cell cycle was evaluated using the flow cytometry method.</div><div>The results of the SEM study showed that the synthesized nanoparticles had a spherical morphology and a diameter of less than 200 nm. The zeta potential was determined to be 39.1 mV using a DLS device. The results of the FTIR study also showed successful interactions between niosome and daphnetin. According to the flow cytometry results, the frequency of early apoptosis and delayed apoptosis was significantly higher in the cells treated with the IC₅₀ concentration of daphnetin-loaded nanoparticles than in the group treated with daphnetin and free niosome. The expression of apoptotic genes was also increased in the group treated with the IC₅₀ concentration of the loaded nanoparticles and the expression of antimetastatic genes was decreased. The results of the cell migration assay (scratch test) also show that treatment with the IC₅₀ concentration of the loaded nanoparticles can effectively control cell migration. Therefore, they can be considered as chemotherapeutic agents against breast cancer.</div></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"14 ","pages":"Article 100139"},"PeriodicalIF":2.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143816727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to “Immunomodulatory effects of β-defensin 2 on tumor associated macrophages induced antitumor function in breast cancer” [Adv. Cancer Biol. – Metastasis 7 (2023) 100102]","authors":"Sonam Agarwal,&nbsp;Anita Chauhan,&nbsp;Pramod Kumar Gautam","doi":"10.1016/j.adcanc.2025.100137","DOIUrl":"10.1016/j.adcanc.2025.100137","url":null,"abstract":"<div><div>This article has been retracted: please see Elsevier Policy on Article Withdrawal (<span><span>https://www.elsevier.com/about/policies/article-withdrawal</span><svg><path></path></svg></span>).</div><div>This article has been retracted at the request of the Editor-in-Chief.</div><div>Concern was raised about validity and reliability of the data, experimental procedures, data analysis methods and consequently the result of the article.</div><div>The Editors requested the corresponding author to repeat the experiments at least three times and provide the raw data and standard deviations for the statistically evaluated results. However, the authors did not follow the Editors' recommendations and were unable to provide adequate response for comment. The overall validity of the results could not be confirmed. Therefore, the Editor-in-Chief decided to retract the article.</div></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"13 ","pages":"Article 100137"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143610692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EPHA5 enhances stemness and decreases gefitinib sensitivity via Wnt signaling pathway in non-small lung cancer","authors":"Jie Li ,&nbsp;Yehan Zhu","doi":"10.1016/j.adcanc.2025.100135","DOIUrl":"10.1016/j.adcanc.2025.100135","url":null,"abstract":"<div><h3>Objective</h3><div>Non-small lung cancer (NSCLC) is the most prevalent form of lung cancer, and it is often associated with poor patient outcomes. Erythropoietin-producing hepatocellular receptor A5 (EPHA5), a member of the Eph tyrosine kinase receptor family, has been implicated in various stages of tumor progression. However, the specific role of EPHA5 in NSCLC remains poorly understood. This study aims to explore the influence of EPHA5 on the stemness of NSCLC cancer cells and their sensitivity to gefitinib, while also investigating the underlying mechanisms involved.</div></div><div><h3>Methods</h3><div>EPHA5 expression was suppressed using small interfering ribonucleic acids (siRNAs), while qPCR and Western blot were applied to analyze the knockdown efficiency. Subsequently, the expressions of stem cell-related markers, such as SOX2, Nanog, KLF4, Oct4, and β-catenin, were detected and quantified via qPCR and Western blot during the experiment, while CD133-positive cells were analyzed via flow cytometry. Gefitinib sensitivity was evaluated in EPHA5-knockdown cells. The Wnt activator, CHIR-99021, was employed to rescue β-catenin expression.</div></div><div><h3>Results</h3><div>EPHA5 expression was elevated in NSCLC cell lines (NCI-H460 and NCI-H1229) but considerably downregulated by siRNAs. EPHA5 knockdown alleviated stemness, enhanced gefitinib sensitivity, and suppressed Wnt activation, as evidenced by lower CD133-positive cells, and decreased expression of Sox2, Nanog, KLF4, Oct4, and β-catenin. The Wnt activator reversed the inhibitory effect of EPHA5 on cancer cell stemness by upregulating β-catenin.</div></div><div><h3>Conclusion</h3><div>Silencing the expression of EPHA5 can reduce NSCLC stemness and enhance gefitinib sensitivity by inhibiting the Wnt signaling pathway.</div></div><div><h3>Strengths and limitations of this study</h3><div>We find EPHA5 enhances stemness and decreases gefitinib sensitivity via Wnt signaling pathway of non-small cell lung cancer but prognostic follow-up of lung adenocarcinoma patients in this study is lacking.</div></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"13 ","pages":"Article 100135"},"PeriodicalIF":2.0,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143474318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HDAC3-mediated deacetylation of p21 stabilizes protein levels and promotes 5-FU resistance in colorectal cancer cells","authors":"Wei Jin ,&nbsp;Jue-jue Wang ,&nbsp;Yan-fei Feng ,&nbsp;Bing Chen,&nbsp;Zhao-hua Hu","doi":"10.1016/j.adcanc.2025.100136","DOIUrl":"10.1016/j.adcanc.2025.100136","url":null,"abstract":"<div><div>5-Fluorouracil (5-FU) remains a cornerstone in colorectal cancer (CRC) chemotherapy; however, its clinical efficacy is often compromised by the development of resistance. Histone deacetylase 3 (HDAC3) has been implicated in chemoresistance across various cancers, yet its precise role in mediating 5-FU resistance in CRC remains poorly understood. In this study, we established a 5-FU-resistant CRC cell line (HCT116/5-FU) by gradually exposing parental HCT116 cells to increasing 5-FU concentrations. Screening of HDAC family members revealed significant upregulation of HDAC3 at both mRNA and protein levels in resistant cells. Mechanistically, we show that HDAC3 promotes 5-FU resistance by destabilizing the cyclin-dependent kinase inhibitor p21 through deacetylation, enhancing its ubiquitination and subsequent degradation. This HDAC3-mediated reduction in p21 levels disrupts cell cycle control, contributing to chemoresistance. Importantly, treatment with the HDAC3-specific inhibitor RGFP966 restored p21 stability, reduced colony formation, and sensitized HCT116/5-FU cells to 5-FU. Xenograft experiments further validated the synergistic efficacy of RGFP966 and 5-FU in vivo. These findings identify HDAC3 as a critical regulator of 5-FU resistance through modulation of p21 stability and suggest that combining HDAC3 inhibitors with conventional chemotherapy represents a promising strategy to overcome chemoresistance in CRC patients.</div></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"14 ","pages":"Article 100136"},"PeriodicalIF":2.0,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143847452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unravelling the oncogenic potential and prognostic significance of MAPT in breast cancer: An In-Silico inhibition of MAPT by paclitaxel","authors":"Asma Jan,&nbsp;Shazia Sofi,&nbsp;Manzoor Ahmad Mir","doi":"10.1016/j.adcanc.2025.100134","DOIUrl":"10.1016/j.adcanc.2025.100134","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer is the second top mortality of women globally. A major difficulty in therapeutic therapy is the disease's heterogeneity. However, modern discoveries in molecular biology and immunology have made it possible to create highly focused medicines for a variety of breast tumor subtypes. The fundamental aim of targeted treatments is to inhibit the growth of tumors by blocking the activity of a particular target or molecule. Morphological alterations in neuronal-glial cells have been linked to breast cancer (BC) on several occasions. However, the processes by which these neuronal proteins are regulated remain unclear despite their association with cancer. Analysis of the expression of genes in tissues of human BC has recognized microtubule-binding protein Tau to be a newly identified marker of response to paclitaxel and a modulator of paclitaxel sensitivity. In terms of taxane resistance pathways, those involving MAPs (microtubule-associated proteins) such as Tau are crucial. Reduced concentration of the Tau protein makes the microtubules of the mitochondrion and the cytoskeleton more vulnerable to the effects of the drug paclitaxel, which can disrupt mitosis and interfere with cell signalling. Clinical and preclinical data from the past several years support the hypothesis that ER induces the gene MAP-Tau and the resulting expression of the Tau protein influences the susceptibility of malignant cells to taxanes.</div></div><div><h3>Aim</h3><div>This study illustrates the expression pattern and prognostic significance of MAPT (Microtubule-Associated Proteins Tau) in BC and targeting MAPT using Paclitaxel drug.</div></div><div><h3>Methods</h3><div>The present study employed both <strong><em>In Silico</em></strong> and <strong><em>In Vitro</em></strong> methodologies to evaluate the expression profile, prognostic, and therapeutic value of the MAPT gene in BC and discover the interactions of MAPT in breast cancer pathogenesis.</div></div><div><h3>Results</h3><div>The <strong><em>In-Silico</em></strong> and <strong><em>In-Vitro</em></strong> studies have also revealed that patients with BC will have much better therapeutic responses when MAPT is inhibited in addition to normal therapies because overexpression of MAPT promotes tumor formation.</div></div><div><h3>Conclusion</h3><div>Overall, our research indicates that MAPT is associated with tumor growth in BC cells and its dysregulation has been implicated in breast cancer pathogenesis.</div></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"14 ","pages":"Article 100134"},"PeriodicalIF":2.0,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143643580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Silencing of long non-coding RNAs MIR22HG, LNCTAM34A, and TP53TG1 triggers cell survival/proliferation and inhibits apoptosis in women's breast cancer","authors":"Ahmed Al-Kateb ,&nbsp;Roozbeh Heidarzadehpilehrood ,&nbsp;Maryam Pirhoushiaran ,&nbsp;Rasoul Abdollahzadeh ,&nbsp;Mojtaba Saffari ,&nbsp;Keivan Majidzadeh-A ,&nbsp;Sepideh Mehrpoor Layeghi ,&nbsp;Mohammad Hossein Modarressi","doi":"10.1016/j.adcanc.2025.100133","DOIUrl":"10.1016/j.adcanc.2025.100133","url":null,"abstract":"<div><h3>Background</h3><div>This study investigated the functional and translational role of long non-coding RNAs (lncRNAs), specifically MIR22HG, LNCTAM34A, and TP53TG1, in breast cancer (BC).</div></div><div><h3>Methods</h3><div>The expression of the lncRNAs was measured using RT-qPCR. Knockdown experiments using siRNA were conducted in breast cancer cell lines (MDA-MB-231, MDA-MB-453, and MCF-7) to assess the functional impact of silencing these lncRNAs. Cell proliferation, colony formation, invasion, migration, and apoptosis assays were performed to evaluate phenotypic changes.</div></div><div><h3>Results</h3><div>The expression of MIR22HG, LNCTAM34A, and TP53TG1 was significantly decreased in tumor tissues compared to NATs (<em>p</em> &lt; 0.05). Lower expression of these lncRNAs correlated with advanced TNM stage and grade groups (<em>p</em> &lt; 0.05). MIR22HG was overexpressed in the BC cell lines MDA-MB-231 and MCF-7, while LNCTAM34A and TP53TG1 were upregulated in MDA-MB-453 and MCF-7 BC cell lines. Silencing these lncRNAs led to a significant increase in cell proliferation, colony formation, invasion, and migration (<em>p</em> &lt; 0.001). Additionally, apoptosis was significantly decreased in cells with silenced lncRNAs (<em>p</em> &lt; 0.05). Knockdown of MIR22HG, LNCTAM34A, and TP53TG1 in BC cells resulted in increased cell proliferation and colony formation. Silencing of these lncRNAs significantly increased cell migration and invasion. The silencing of MIR22HG, LNCTAM34A, and TP53TG1 decreased apoptosis in BC cells.</div></div><div><h3>Conclusion</h3><div>Study demonstrates that MIR22HG, LNCTAM34A, and TP53TG1 function as tumor suppressors in breast cancer. Downregulation of these lncRNAs promotes tumor progression by enhancing cell proliferation, invasion, and migration, while inhibiting apoptosis.</div></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"13 ","pages":"Article 100133"},"PeriodicalIF":2.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143422505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysregulated key long non-coding RNAs TP53TG1, RFPL1S, DLEU1, and HCG4 associated with epithelial-mesenchymal transition (EMT) in castration-resistant prostate cancer","authors":"Tahmineh Mehrabi ,&nbsp;Roozbeh Heidarzadehpilehrood ,&nbsp;Meysam Mobasheri ,&nbsp;Tabassom Sobati ,&nbsp;Masoumeh Heshmati ,&nbsp;Maryam Pirhoushiaran","doi":"10.1016/j.adcanc.2025.100132","DOIUrl":"10.1016/j.adcanc.2025.100132","url":null,"abstract":"<div><h3>Background</h3><div>Castration-resistant prostate cancer (CRPC) is the severe and metastatic form of prostate cancer and demands effective, reliable diagnostic and therapeutic approaches. It has been shown that long non-coding RNAs (lncRNAs) dysregulations promote metastasis in tumors. The current research aim is to identify dysregulated lncRNAs in metastatic CRPC.</div></div><div><h3>Materials and methods</h3><div>R programs along with multiple packages were applied to identify novel lncRNAs dysregulated in CRPC. Raw data of clinical samples were obtained from NCBI-GSE74685, which consisted of metastatic and non-metastatic CRPC samples, and was analyzed through a limma package of R with defined cutoff criteria as adjusted <em>P-value</em> &lt; 0.05 and |Fold Change = FC| ≥ ±1. To further understand lncRNA co-expression gene modules, WGCNA analysis, hub-gene identification, and pathway enrichment were performed.</div></div><div><h3>Results</h3><div>Four dysregulated lncRNAs were identified with more than a two-fold change in expression levels, including TP53TG1, RFPL1S, DLEU1, and HCG4. WGCNA analysis results in royal blue, salmon, light cyan, and blue co-expression modules with dysregulated lncRNAs. According to a pathway enrichment study, these co-expressed modules showed enrichment in highly relevant pathways to the CRPC metastatic process, including mesenchymal-to-epithelial transition, purine metabolism, C-MYB transcription factor network, and immune system. In addition, SOD2, PRKCA, IL6, and ITGAM were identified as hub genes.</div></div><div><h3>Conclusion</h3><div>The current study suggests dysregulation of TP53TG1, RFPL1S, DLEU1, and HCG4 lncRNAs and corresponding hub genes may promote CRPC metastasis through the EMT pathways.</div></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"13 ","pages":"Article 100132"},"PeriodicalIF":2.0,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143151537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upregulation of mitochondrial function is associated with advanced prostate cancer","authors":"Valentin Baumgartner ,&nbsp;Thomas Paul Scherer ,&nbsp;Ashkan Mortezavi ,&nbsp;Niels Rupp ,&nbsp;Holger Moch ,&nbsp;Peter Wild ,&nbsp;Susanne Dettwiler ,&nbsp;Miriam Wanner ,&nbsp;Dominik Enderlin ,&nbsp;Souzan Salemi ,&nbsp;Daniel Eberli","doi":"10.1016/j.adcanc.2024.100131","DOIUrl":"10.1016/j.adcanc.2024.100131","url":null,"abstract":"<div><h3>Background</h3><div>The mitochondrial metabolism in prostate cancer (PCa) is of great importance due the unique metabolic shift from glycolysis to oxidative phosphorylation. In this study, we aimed to analyze the expression level of mitochondrial markers TOM20, DRP1 and OPA1 in benign and malignant tissue, to assess if these markers are associated with different grade and stage of PCa.</div></div><div><h3>Materials and methods</h3><div>This study assessed TOM20, DRP1, and OPA1 expression in formalin-fixed, paraffin-embedded prostate tissue samples, including benign and malignant tissue specimen. Immunohistochemistry on tissue microarrays was conducted, with staining intensities scored semi-quantitatively. Statistical analyses evaluated associations with PCa grade and stage. A survival analysis for biochemical recurrence (RFS), overall survival (OS) and disease specific survival (DSS) was performed using multivariate Cox regression analysis to assess prognostic properties of the markers.</div></div><div><h3>Results</h3><div>In total, 527 patients were included in our analysis, which composed of 45 (8.5 %) benign prostate hyperplasia (BPH) and 482 (91.5 %) PCa samples (436 localized (90.5 %) and 46 (9.5 %) metastatic). Immunoreactivity for TOM20, DRP1 and OPA1 was strong in 2 of 43 (4.7 %), 1 of 43 (2.3 %) and 0 of 43 (0 %) of BPH control tissue. Strong marker expression was significantly increased in radical prostatectomy specimen (TOM20: 111/371 (29.9 %), DRP1: 89/373 (23.9 %), OPA1: 60/371 (16.2 %), <em>p</em> &lt; 0.001) and in metastatic tissue (TOM20: 22/42 (52.4 %), DRP1: 14/42 (33.3 %), OPA1: 21/41 (51.2 %), <em>p</em> &lt; 0.001). None of the markers demonstrated prognostic properties for RFS, OS, and DSS.</div></div><div><h3>Conclusion</h3><div>A strong association between the expression of the mitochondrial markers TOM20, DRP1 and OPA1 and PCa aggressiveness was demonstrated. However, these markers were not found to be prognostic regarding RFS, OS and DSS. Future studies are needed focusing on the underlying mechanisms of the upregulation of mitochondrial metabolism in aggressive PCa and evaluate potential therapeutic implications.</div></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"13 ","pages":"Article 100131"},"PeriodicalIF":2.0,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}